Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
29 April 2022Website:
http://www.hillevax.comNext earnings report:
14 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Thu, 20 Jun 2024 21:04:48 GMTDividend
Analysts recommendations
Institutional Ownership
HLVX Latest News
BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the Guggenheim 6th Annual Biotechnology Conference in New York, New York on Wednesday, February 7, 2024 at 2:00 p.m. EST. HIL-214, HilleVax's investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing Phase 2b study NEST-IN1 will be topics of discussion.
BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California on Monday, January 8, 2024 at 4:30 p.m. EST / 1:30 p.m. PST. HIL-214, HilleVax's investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing Phase 2b study NEST-IN1 will be topics of discussion.
HilleVax, Inc. (HLVX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference in New York, New York on Monday, November 6, 2023 at 3:10 p.m. EST and at the Stifel Healthcare Conference in New York, New York, on Tuesday, November 14, 2023 at 11:30 a.m. EST. HIL-214, HilleVax's investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing Phase 2b study NEST-IN1 will be topics of discussion.
BOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the 2023 Cantor Global Healthcare Conference in New York, New York on Thursday, September 28, 2023 at 12:40 p.m. EST. HIL-214, HilleVax's investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing Phase 2b study NEST-IN1 will be topics of discussion.
HilleVax is developing a virus-like particle vaccine candidate, HIL-214, for norovirus-induced acute gastroenteritis. Norovirus is highly contagious and causes a significant disease burden, with millions affected and billions in costs. HIL-214 has shown promising safety and immunogenicity profiles in Phase I & II trials, with ongoing Phase 2b trials in infants.
The average of price targets set by Wall Street analysts indicates a potential upside of 56.8% in HilleVax, Inc. (HLVX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
What type of business is HilleVax?
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
What sector is HilleVax in?
HilleVax is in the Healthcare sector
What industry is HilleVax in?
HilleVax is in the Biotechnology industry
What country is HilleVax from?
HilleVax is headquartered in United States
When did HilleVax go public?
HilleVax initial public offering (IPO) was on 29 April 2022
What is HilleVax website?
https://www.hillevax.com
Is HilleVax in the S&P 500?
No, HilleVax is not included in the S&P 500 index
Is HilleVax in the NASDAQ 100?
No, HilleVax is not included in the NASDAQ 100 index
Is HilleVax in the Dow Jones?
No, HilleVax is not included in the Dow Jones index
When does HilleVax report earnings?
The next expected earnings date for HilleVax is 14 August 2024